121例膀胱癌术后吡柔比星灌注预防肿瘤复发疗效观察  

Clinical Study on Intravesical Instillation of Pirarubicin (THP) for Prevention of Postoperative Recurrence of Bladder Cancer

作　　者：关有良[1] 张玥 

机构地区：[1]辽宁医学院附属第一医院,辽宁锦州121000 [2]辽宁锦州石油六厂职工医院,辽宁锦州121000

出　　处：《中国医学工程》2011年第7期56-57,共2页China Medical Engineering

摘　　要：目的探讨吡柔比星(THP)灌注对膀胱癌术后预防肿瘤复发的临床效果。方法选取我院自2007年3月～2009年4月收治的121例膀胱癌术后患者作为研究对象,均于术后给予吡柔比星膀胱灌注治疗,每次30mg,每周治疗1次,连续治疗2个月后改为每月治疗1次,总疗程为12个月,观察治疗效果。结果本组121例患者坚持完成灌注治疗者118例,对118例患者进行为期12个月的随访观察,每3个月做膀胱镜及相关病理检查,术后6个月复发7例,6个月复发率为5.1%;术后12个月复发12例,12个月复发率为10.2%;总复发19例,总复发率为15.3%。治疗期间副反应轻微。结论应用吡柔比星行膀胱灌注化疗对预防膀胱癌复发疗效满意,患者耐受性好,副作用少,提高患者术后生存期。【Objective】 To study the effects of intravesical instillation of pirarubicin（THP） to prevent postoperative recurrence of superficial bladder cancer after partial cystectomy or transurethral resection of bladder tumor（TUR-Bt）.【Methods】 121 cases of bladder cancer were reviewed from March 2007 to April 2009.Intravesical instillation of 30mg of THP was given to the patients once a week for 8 weeks and subsequently once a month for 8 months.【Results】 118 of 121 cases fulfilled the intravesical instillation.The follow-up time was 12 months.Cystoscopy was taken every 3 months for each patient.7（5.1%） cases of recurrence were found at sixth month and 12（10.2%） cases one year later.【Conclusion】 Intravesical instillation of THP is effective for prevention of postoperative recurrence of superficial bladder cancer with fewer side effects.

关 键 词：膀胱癌 吡柔比星 肿瘤复发 

分 类 号：R737.14[医药卫生—肿瘤]